Can a common drug prevent relapse after stem cell transplant?
NCT ID NCT03850418
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests whether a low dose of the drug azacitidine can help maintain or increase the level of donor cells in patients with certain blood cancers (MDS, AML, CMML, MPN) after a stem cell transplant. The goal is to reduce the chance of the cancer coming back. About 43 adults aged 18-75 who have low donor cell levels after transplant will receive azacitidine to see if it safely improves donor chimerism.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry ford hospital
RECRUITINGDetroit, Michigan, 48202, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.